Investigating how ETS1 influences survival in a type of leukemia called T-ALL
Official title: Defining the genetic mechanisms of ETS1 dependency in Notch-activated T Cell Acute Lymphoblastic Leukemia (T-ALL)
Funded at University of Michigan at Ann Arbor · NIH-10995385 · Data updated 2026-11-12
This study is looking at how a protein called ETS1 affects T cell acute lymphoblastic leukemia (T-ALL) and hopes to find a way to make T-ALL cells less able to survive, which could lead to better treatments with fewer side effects for patients.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | August 1, 2024 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $49,490 |
| NIH project number | 1F30CA288021-01A1 |
| Project ID | NIH-10995385 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with T cell acute lymphoblastic leukemia, particularly those with mutations in the NOTCH1 pathway.
✕Less likely to help
Patients with other types of leukemia or those without NOTCH1 mutations may not benefit from this research.
What this research studies
This research focuses on understanding the role of the ETS1 transcription factor in T cell acute lymphoblastic leukemia (T-ALL), a cancer that often involves mutations in the NOTCH1 signaling pathway. The study aims to explore how inhibiting ETS1 can impair the survival of T-ALL cells while potentially causing fewer side effects compared to traditional Notch inhibitors. By identifying specific genetic elements that ETS1 regulates, the research seeks to uncover new therapeutic targets that could improve treatment outcomes for patients with T-ALL.
Why it matters
Potential benefit: If successful, this research could lead to more effective and less toxic treatment options for patients with T-ALL.
How similar studies have gone: Previous research has shown promise in targeting ETS1 for leukemia treatment, suggesting that this approach could be a viable option.
Where this research is happening
-
University of Michigan at Ann Arbor
Ann Arbor, United States Active
Researchers
- Principal investigator: Lin, Karena Hsijan — University of Michigan at Ann Arbor
- Study coordinator: Lin, Karena Hsijan
Related research
Other NIH-funded projects on the same topics.
-
Caregiver-led mobile tool to support healthy habits for kids treated for ALL
A caregiver-directed mobile program helps children who were treated for acute lymphoblastic leukemia build healthier daily routines.
-
Genomics of childhood ALL across global populations
A wide-ranging study looks at how inherited genetics influence the risk of childhood acute lymphoblastic leukemia around the world.
-
Genomics of childhood ALL across diverse populations
A large international study will look at why children everywhere get acute lymphoblastic leukemia and how genetics may influence risk.
-
Combinatorial targeting for high-risk B-cell ALL treatment
A research effort at West Virginia University is exploring a combination therapy for adult B-cell acute lymphoblastic leukemia using targeted gene silencing and a small-molecule compound to improve treatment in patients.
-
Understanding why Latino children have a higher risk of childhood ALL
This project looks at why Latino children are more likely to develop acute lymphoblastic leukemia and whether genetic ancestry plays a role, with the goal of improving prevention and outcomes.
-
Targeting obesity to improve survival for children with ALL
A new approach explores whether reducing obesity-related factors can make chemotherapy work better for kids with acute lymphoblastic leukemia.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.